arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

AIM ImmunoTech Inc.

AIM
$0.27 ▲ +0.01 (+3.74%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

AIM ImmunoTech Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth -48.2%
Op. Margin
ROIC 173.6%
FCF / Share $-6.77
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.46
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$88.00K
↓ -48.2%
Net Income Profit after all expenses
$-13.96M
↑ +19.4%
FCF / Share Free cash flow per share
$-6.77
↑ +74.6%
Long-Term Debt Long-term obligations
$4.48M
↑ +59.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Financial Health
63
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters